Infervision vs Lunit
Two Asian origin imaging AI companies that both reached international markets, with different centres of gravity. Lunit is cancer focused across chest radiograph and mammography, publicly listed, with the deeper evidence base in screening populations, which is the setting where a false positive rate multiplies across a large healthy denominator. Infervision spans lung nodule detection and chest interpretation across modalities with United States operations alongside its origin market, which gives an American buyer a closer support relationship. For a screening programme, Lunit's evidence is the more relevant. For a health system wanting breadth across the imaging estate from one vendor, Infervision reaches further. Ask both for performance at your prevalence rather than in their validation cohorts.
- Cancer detection across chest radiograph and mammography with a listed parent and regulatory footprints in multiple markets.
- The evidence base in screening populations is deeper than most detection vendors, which is where both sensitivity and specificity bite.
- For a screening programme, a portfolio built around cancer detection is a closer fit than general findings reading.
- Its suite spans lung nodule detection and chest interpretation with United States operations alongside its origin market.
- Coverage extends across modalities rather than radiography alone, so one vendor reaches more of the imaging estate.
- For a buyer wanting an established American support relationship from a non Western vendor, that presence matters.
Side by Side
| Axis | I Infervision |
L Lunit |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both are non Western origin imaging vendors and the pattern this index records applies to both: regulatory effort follows market access while commercial assurance documentation is thinner, so ask for attestations and business associate terms explicitly. Findings counts are not comparable between vendors because each counts differently.
Prevalence in your own population determines the false positive burden more than published sensitivity does, and neither publishes performance stratified that way, which matters most in screening where the denominator is large and healthy.